SCHEMBL5098145

SCHEMBL5098145

COC(=O)C(c1ccc(O)cc1)N(C)C

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.51
ESR2 Q92731 3/20 0.51
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP13 P45452 1/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
CA14 Q9ULX7 2/20 0.42
KMT2A Q03164 1/20 0.40
MIF P14174 3/20 0.40
PDCD1 Q15116 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
ESRRB O95718 1/20 0.37
TYR P14679 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28260381 0.84 L3MBTL1 (0.47) ALDH1A1
SCHEMBL6639945 0.83 KMT2A (0.60) KMT2AALDH1A1
SCHEMBL18681391 0.81 ESR1 (0.42) ESR1ESR2MMP2MMP9MMP13
SCHEMBL10933400 0.79 SRC (0.46) ESR1ESR2CA12CA1CA2
SCHEMBL1960706 0.79 SRC (0.46) ESR1ESR2CA12CA1CA2
SCHEMBL1443507 0.77 ESR1 (0.44) ESR1ESR2MMP2MMP9MMP13
Hydrochloric Acid SCHEMBL3453552 0.77 ESR1 (0.46) ESR1ESR2CA12CA1CA2
SCHEMBL384968 0.76 ESR1 (0.58) ESR1ESR2MMP2MMP9MMP13
SCHEMBL8406161 0.76 ESR1 (0.58) ESR1ESR2MMP2MMP9MMP13
SCHEMBL5092444 0.76 FFAR1 (0.54) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348017-B2 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin SHISEIDO CO., LTD. (JP) 2008-03-25 US disclosed
EP-1422224-B1 DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN SHISEIDO CO LTD (JP) 2007-12-19 EP disclosed
CN-1319957-C Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin SHISEIDO CO LTD (JP) 2007-06-06 CN disclosed
US-20040236111-A1 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin SHISEIDO CO., LTD. (JP) 2004-11-25 US disclosed
CN-1549809-A Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin ������������ʽ���� 2004-11-24 CN disclosed
EP-1422224-A1 DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN Shiseido Co., Ltd. (JP) 2004-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236111-A1 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin MMP1, MMP2, MMP3 ESR1 4567/4885ESR2 2846/4885MMP2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.